![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Vol. 61, Issue 3, 495-506, March 2002
Department of Pharmacology and Toxicology, The University of Texas
Medical Branch, Galveston, Texas.
Midazolam (MDZ) oxidation by recombinant CYP3A4 purified from
Escherichia coli and 30 mutants generated at 15 different substrate recognition site positions has been studied to
determine the role of individual residues in regioselectivity and to
investigate the possible existence of multiple binding sites. Initial
results showed that oxidation of MDZ by CYP3A4 causes time- and
concentration-dependent enzyme inactivation with
KI and kinact
values of 5.8 µM and 0.15 min
1, respectively. The
different time courses of MDZ hydroxylation by mutants that
predominantly formed 1'-OH MDZ as opposed to 4-OH MDZ provided strong
evidence that the 1'-OH MDZ pathway leads to CYP3A4 inactivation.
Correlational analysis of 1'-OH formation versus 4-OH formation by the
mutants supports the inference that the two metabolites result from the
binding of MDZ at two separate sites. Thus, substitution of residues
Phe-108, Ile-120, Ile-301, Phe-304, and Thr-309 with a larger amino
acid caused an increase in the ratio of 1'-OH/4-OH MDZ formation,
whereas substitution of residues Ser-119, Ile-120, Leu-210, Phe-304,
Ala-305, Tyr-307, and Thr-309 with a smaller amino acid decreased this
ratio. Kinetic analyses of nine key mutants revealed that the
alteration in regioselectivity is caused by a change in kinetic
parameters (Vmax and
KM) for the formation of both metabolites in
most cases. The study revealed the role of various active-site residues
in the regioselectivity of MDZ oxidation, identified the metabolic
pathway that leads to enzyme inactivation, and provided an indication
that the two proposed MDZ binding sites in CYP3A4 may be partially overlapping.
This article has been cited by other articles:
|
|
 |
|
  R. A. Stringer, C. Strain-Damerell, P. Nicklin, and J. B. Houston Evaluation of Recombinant Cytochrome P450 Enzymes as an in Vitro System for Metabolic Clearance Predictions Drug Metab. Dispos., May 1, 2009; 37(5): 1025 - 1034. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Miyazaki, K. Nakamura, Y. Fujita, F. P. Guengerich, R. Horiuchi, and K. Yamamoto Defective Activity of Recombinant Cytochromes P450 3A4.2 and 3A4.16 in Oxidation of Midazolam, Nifedipine, and Testosterone Drug Metab. Dispos., November 1, 2008; 36(11): 2287 - 2291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kapelyukh, M. J. I. Paine, J.-D. Marechal, M. J. Sutcliffe, C. R. Wolf, and G. C. K. Roberts Multiple Substrate Binding by Cytochrome P450 3A4: Estimation of the Number of Bound Substrate Molecules Drug Metab. Dispos., October 1, 2008; 36(10): 2136 - 2144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Kang, M. Liao, M. R. Wester, J. S. Leeder, R. E. Pearce, and M. A. Correia CYP3A4-Mediated Carbamazepine (CBZ) Metabolism: Formation of a Covalent CBZ-CYP3A4 Adduct and Alteration of the Enzyme Kinetic Profile Drug Metab. Dispos., March 1, 2008; 36(3): 490 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-J. Lee, S. S. Lee, H.-E. Jeong, J.-H. Shon, J.-Y. Ryu, Y. E. Sunwoo, K.-H. Liu, W. Kang, Y.-J. Park, C.-M. Shin, et al. The CYP3A4*18 Allele, the Most Frequent Coding Variant in Asian Populations, Does Not Significantly Affect the Midazolam Disposition in Heterozygous Individuals Drug Metab. Dispos., November 1, 2007; 35(11): 2095 - 2101. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Li, H. Liu, X. Luo, W. Zhu, Y. Tang, J. R. Halpert, and H. Jiang Possible Pathway(s) of Metyrapone Egress from the Active Site of Cytochrome P450 3A4: A Molecular Dynamics Simulation Drug Metab. Dispos., April 1, 2007; 35(4): 689 - 696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Carr, R. Norcross, Y. Fang, P. Lu, A. D. Rodrigues, M. Shou, T. Rushmore, and C. Booth-Genthe Characterization of the Rhesus Monkey CYP3A64 Enzyme: Species Comparisons of CYP3A Substrate Specificity and Kinetics Using Baculovirus-Expressed Recombinant Enzymes Drug Metab. Dispos., October 1, 2006; 34(10): 1703 - 1712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-D. Marechal, J. Yu, S. Brown, I. Kapelioukh, E. M. Rankin, C. R. Wolf, G. C. K. Roberts, Mark. J. I. Paine, and M. J. Sutcliffe IN SILICO AND IN VITRO SCREENING FOR INHIBITION OF CYTOCHROME P450 CYP3A4 BY COMEDICATIONS COMMONLY USED BY PATIENTS WITH CANCER Drug Metab. Dispos., April 1, 2006; 34(4): 534 - 538. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Tuvesson, I. Hallin, R. Persson, B. Sparre, P. O. Gunnarsson, and J. Seidegard CYTOCHROME P450 3A4 IS THE MAJOR ENZYME RESPONSIBLE FOR THE METABOLISM OF LAQUINIMOD, A NOVEL IMMUNOMODULATOR Drug Metab. Dispos., June 1, 2005; 33(6): 866 - 872. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Klees, P. Sheffels, O. Dale, and E. D. Kharasch METABOLISM OF ALFENTANIL BY CYTOCHROME P4503A (CYP3A) ENZYMES Drug Metab. Dispos., March 1, 2005; 33(3): 303 - 311. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A.-C. Egnell, J. B. Houston, and C. S. Boyer Predictive Models of CYP3A4 Heteroactivation: In Vitro-in Vivo Scaling and Pharmacophore Modeling J. Pharmacol. Exp. Ther., March 1, 2005; 312(3): 926 - 937. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Gupta, Y. A. He, K. S. Patrick, J. R. Halpert, and N. H. Bell CYP3A4 Is a Vitamin D-24- and 25-Hydroxylase: Analysis of Structure Function by Site-Directed Mutagenesis J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 1210 - 1219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Huang, Y. S. Lin, D. J. McConn II, J. C. Calamia, R. A. Totah, N. Isoherranen, M. Glodowski, and K. E. Thummel EVIDENCE OF SIGNIFICANT CONTRIBUTION FROM CYP3A5 TO HEPATIC DRUG METABOLISM Drug Metab. Dispos., December 1, 2004; 32(12): 1434 - 1445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Paine, A. B. Criss, and P. B. Watkins TWO MAJOR GRAPEFRUIT JUICE COMPONENTS DIFFER IN INTESTINAL CYP3A4 INHIBITION KINETIC AND BINDING PROPERTIES Drug Metab. Dispos., October 1, 2004; 32(10): 1146 - 1153. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. M. Jones and J. B. Houston SUBSTRATE DEPLETION APPROACH FOR DETERMINING IN VITRO METABOLIC CLEARANCE: TIME DEPENDENCIES IN HEPATOCYTE AND MICROSOMAL INCUBATIONS Drug Metab. Dispos., September 1, 2004; 32(9): 973 - 982. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Williams, J. Cosme, D. M. Vinkovic, A. Ward, H. C. Angove, P. J. Day, C. Vonrhein, I. J. Tickle, and H. Jhoti Crystal Structures of Human Cytochrome P450 3A4 Bound to Metyrapone and Progesterone Science, July 30, 2004; 305(5684): 683 - 686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Walsky and R. S. Obach VALIDATED ASSAYS FOR HUMAN CYTOCHROME P450 ACTIVITIES Drug Metab. Dispos., June 1, 2004; 32(6): 647 - 660. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yamaguchi, K. K. Khan, Y. A. He, Y. Q. He, and J. R. Halpert TOPOLOGICAL CHANGES IN THE CYP3A4 ACTIVE SITE PROBED WITH PHENYLDIAZENE: EFFECT OF INTERACTION WITH NADPH-CYTOCHROME P450 REDUCTASE AND CYTOCHROME B5 AND OF SITE-DIRECTED MUTAGENESIS Drug Metab. Dispos., January 1, 2004; 32(1): 155 - 161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Galetin, S. E. Clarke, and J. B. Houston MULTISITE KINETIC ANALYSIS OF INTERACTIONS BETWEEN PROTOTYPICAL CYP3A4 SUBGROUP SUBSTRATES: MIDAZOLAM, TESTOSTERONE, AND NIFEDIPINE Drug Metab. Dispos., September 1, 2003; 31(9): 1108 - 1116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. C. Patki, L. L. von Moltke, and D. J. Greenblatt IN VITRO METABOLISM OF MIDAZOLAM, TRIAZOLAM, NIFEDIPINE, AND TESTOSTERONE BY HUMAN LIVER MICROSOMES AND RECOMBINANT CYTOCHROMES P450: ROLE OF CYP3A4 AND CYP3A5 Drug Metab. Dispos., July 1, 2003; 31(7): 938 - 944. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Galetin, S. E. Clarke, and J. B. Houston Quinidine and Haloperidol as Modifiers of CYP3A4 Activity: Multisite Kinetic Model Approach Drug Metab. Dispos., December 1, 2002; 30(12): 1512 - 1522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. K. Khan, Y. Q. He, M. A. Correia, and J. R. Halpert Differential Oxidation of Mifepristone by Cytochromes P450 3A4 and 3A5: Selective Inactivation of P450 3A4 Drug Metab. Dispos., September 1, 2002; 30(9): 985 - 990. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
